Study: Novel heart failure drug shows big promise

(Nasa/1998, Getty Images/File)
(Nasa/1998, Getty Images/File)
Set Text Size SmallSet Text Size MediumSet Text Size LargeSet Text Size X-Large
Share
Updated: 8/31 9:36 am

A new study reports one of the biggest potential advances against heart failure in more than a decade. Doctors say that a first-of-a-kind, experimental drug cut the chances of death or hospitalization by about 20 percent.

The drug, made by Switzerland-based Novartis, does not have a name yet and is just called LCZ696. If it wins federal approval, doctors say it could quickly change care for more than half of the 6 million Americans and 24 million people worldwide with heart failure.

The study involved nearly 8,500 people and was stopped early once independent monitors saw the Novartis drug was better.

Results were discussed Saturday at a cardiology conference in Barcelona and published by the New England Journal of Medicine.

 

©2014 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Share
NEWSCASTS ON DEMAND
WATCH OUR LIVE NEWSCAST

What's On

All content © Copyright 2014 Intermountain West Communications Company. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.
You may also view our Sitemap

Inergize Digital This site is hosted and managed by Inergize Digital.
Mobile advertising for this site is available on Local Ad Buy.